Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Moderna, Inc.

Market Cap 24.52B 21.15B 19.45B 18.31B 34.4B 2,314B 34.69B 230B 89.73B 1,136B 92.03B 90.07B 3,929B P/E 2026 *
-7.15x
P/E 2027 * -13.1x
Enterprise Value 20.96B 18.08B 16.63B 15.65B 29.41B 1,978B 29.65B 197B 76.71B 971B 78.67B 76.99B 3,359B EV / Sales 2026 *
10x
EV / Sales 2027 * 8.86x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
1 day+1.13%
1 week+34.38%
Current month+30.96%
1 month+26.02%
3 months+14.59%
6 months+102.56%
Current year+109.56%
1 week 49.62
Extreme 49.62
62.3
1 month 43.9
Extreme 43.9
62.3
Current year 29.81
Extreme 29.81
62.3
1 year 22.28
Extreme 22.28
62.3
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 62 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Date Insider Type Main position Quantity % Market Cap.
Jun. 04Fiscal year

Chief Financial Officer

29,301 0.0074%
Jun. 04Fiscal year

General Counsel

29,301 0.0074%
May. 31Fiscal year

Chief Financial Officer

6,147 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
+11.55%+34.38%+141.88%-51.99% 21.98B
-1.11%+1.04%+19.47%-22.36% 62.54B
+0.96%-4.54%+59.60%+194.24% 55.22B
+2.78%+37.00%+37.00%+37.00% 40.9B
+0.48%-0.01%-55.69%-62.30% 35.99B
+1.56%+2.28%+56.98%-33.22% 28.88B
-0.76%-6.07%+43.86%+56.56% 19.93B
+2.00%+4.73%-2.80%+114.61% 16.95B
+2.32%+1.24%+56.95%+95.04% 15.87B
+1.13%-0.02%+68.18%+348.97% 13.05B
Average +1.05%+4.48%+42.54%+67.65% 31.13B
Weighted average by Cap. +0.81%+3.59%+36.62%+50.20%

Financials

2026 *2027 *
Net sales 2.09B 1.81B 1.66B 1.56B 2.94B 198B 2.96B 19.68B 7.66B 97B 7.86B 7.69B 336B 2.51B 2.17B 1.99B 1.88B 3.52B 237B 3.55B 23.61B 9.19B 116B 9.43B 9.23B 403B
Net income -3.4B -2.94B -2.7B -2.54B -4.78B -321B -4.82B -31.99B -12.46B -158B -12.78B -12.5B -545B -1.84B -1.59B -1.46B -1.37B -2.58B -174B -2.6B -17.29B -6.73B -85.22B -6.91B -6.76B -295B
Net Debt -3.56B -3.07B -2.82B -2.66B -4.99B -336B -5.04B -33.46B -13.03B -165B -13.36B -13.07B -570B -2.27B -1.96B -1.8B -1.7B -3.19B -215B -3.22B -21.37B -8.32B -105B -8.53B -8.35B -364B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
26-06-17 61.80 $ +11.55% 12,432,129
26-06-16 55.40 $ +6.27% 13,050,523
26-06-15 52.13 $ +4.45% 6,342,068
26-06-12 49.91 $ +0.54% 5,081,172
26-06-11 49.64 $ +7.94% 6,196,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
61.80USD
Average target price
43.30USD
Spread / Average Target
-29.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!